Categories: News

InflaRx Announces Positive Topline Results from the Single Ascending Dose (SAD) Phase I Study with C5aR Inhibitor INF904

InflaRx Announces Positive Topline Results from the Single Ascending Dose (SAD) Phase I Study with C5aR Inhibitor INF904InflaRx Announces Positive Topline Results from the Single Ascending Dose (SAD) Phase I Study with C5aR Inhibitor INF904
FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare
FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare
AddThis Website Tools
Staff

Share
Published by
Staff
2 years ago

Recent Posts

TriSalus Life Sciences Announces Publication of Safety and Efficacy Results for a Novel Pressure-Enabled Thyroid Embolization Technique

WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology company…

2 hours ago

TriSalus Life Sciences Announces Publication of Safety and Efficacy Results for a Novel Pressure-Enabled Thyroid Embolization Technique

WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology company…

2 hours ago

SetPoint Medical Raises $140 Million in Private Financing and Expands Leadership Team to Support Commercialization of Rheumatoid Arthritis Therapy

VALENCIA, Calif.--(BUSINESS WIRE)--SetPoint Medical, a company dedicated to developing therapies for people living with chronic…

2 hours ago

SetPoint Medical Raises $140 Million in Private Financing and Expands Leadership Team to Support Commercialization of Rheumatoid Arthritis Therapy

VALENCIA, Calif.--(BUSINESS WIRE)--SetPoint Medical, a company dedicated to developing therapies for people living with chronic…

2 hours ago

Windtree Announces Istaroxime has been Chosen for a Plenary Session Presentation at the Heart Failure Society of America 2025

Presentation will be the interim data from the Phase 2 study of istaroxime in SEISMiC…

2 hours ago

FDA Approves Tiziana Life Sciences Phase 2 IND for Multiple System Atrophy

NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”…

2 hours ago